0.7479

5.35% -0.0423

Artelo Biosciences Inc (ARTL)

Overview News Price History Financials Discussions Forecast Stock Split

Artelo Biosciences Inc stock is traded at $0.7479, with a volume of 6.37M. It is down -5.35% in the last 24 hours and down -34.97% over the past month. Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Previous Close:

$0.7902

Open:

$0.7881

24h Volume:

6.37M

Relative Volume:

6.26

Market Cap:

$2.58M

Revenue:

Net Income/Loss:

$-13.47M

P/E Ratio:

-0.0192

EPS:

-38.9215

Net Cash Flow:

$-8.38M

1W Performance:

+6.07%

1M Performance:

-34.97%

6M Performance:

-77.94%

1Y Performance:

-97.51%

1-Day Range:

$0.6902

$0.7999

1-Week Range:

$0.6902

$0.91

52-Week Range:

$0.6902

$31.65

Artelo Biosciences Inc Stock (ARTL) Company Profile

Name

Artelo Biosciences Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

858-925-7049

Address

505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA

Employee

Twitter

@ArteloBio

Next Earnings Date

2026-08-12

Latest SEC Filings

ARTL's Discussions on Twitter

Compare ARTL vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARTL Artelo Biosciences Inc	0.7416	2.75M	0	-13.47M	-8.38M	-38.92
VRTX Vertex Pharmaceuticals Inc	515.52	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.26	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.10	39.31B	5.76B	514.49M	1.10B	4.4813

Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-08-25	Upgrade	D. Boral Capital	Hold → Buy
Feb-12-21	Initiated	Ladenburg Thalmann	Buy

Artelo Biosciences Inc Stock (ARTL) Latest News

10:07 AM

Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus

10:07 AM

08:52 AM

Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire

08:52 AM

Aug 14, 2026

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan

Aug 14, 2026

Aug 13, 2026

Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com

Aug 13, 2026

Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade

Aug 13, 2026

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan

Aug 13, 2026

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results - Yahoo Finance

Aug 13, 2026

Aug 12, 2026

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan

Aug 12, 2026

Aug 10, 2026

Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget

Aug 10, 2026

Artelo Biosciences (ARTL) Rises 1.96% as Shares Hold Between Key Support and ResistanceIchimoku Entry - dars.gov.et

Aug 02, 2026

Jul 28, 2026

Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL - TradingView

Jul 28, 2026

Jul 27, 2026

ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey

Jul 27, 2026

Artelo Biosciences (ARTL) Edges Higher Near Resistance: Key Levels to WatchALMA Signal - dars.gov.et

Jul 27, 2026

Jul 26, 2026